37 completed, 16 terminated, 10 recruiting, 7 unknown. 78 Phase 3, 12 Phase 2.
Follow Pulmonary Fibrosis: new trials by email Literature Review of Pulmonary Fibrosis trials Research Report on Pulmonary Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis BMS-986278 - Pulmonary Fibrosis | Phase 3 | Not yet recruiting | Bristol-Myers Squibb | 2380 | 2026-12-16 | 2026-10-30 |
| Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets NAL ER, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Recruiting | Trevi Therapeutics | 201 | 2026-09-30 | 2026-10-09 |
| Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis Metformin, Matching Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Not yet recruiting | University of Massachusetts, Worcester | 800 | 2026-09-28 | 2026-09-08 |
| Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) INS018_055 tablets, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Recruiting | InSilico Medicine Hong Kong Limited | 320 | 2026-09-09 | 2026-10-13 |
| A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis AK3280, Placebo, Pirfenidone - Idiopathic Pulmonary Fibrosis (IPF) | Phase 3 | Not yet recruiting | Shanghai Ark Biopharmaceutical Co., Ltd. | 263 | 2026-08-31 | 2026-07-22 |
| Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets NAL ER, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Recruiting | Trevi Therapeutics | 306 | 2026-06-29 | 2026-10-13 |
| Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF) Deupirfenidone, Pirfenidone (PFD) - Idiopathic Pulmonary Fibrosis (IPF) | Phase 3 | Recruiting | PureTech | 1100 | 2026-06-26 | 2026-10-23 |
| Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Intravenous immunoglobulin (IVIG), Usual treatment - Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis | Phase 3 | Recruiting | Argyrios Tzouvelekis | 196 | 2026-01-25 | 2026-03-16 |
| A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF) TDI01 - Idiopathic Pulmonary Fibrosis (IPF) | Phase 3 | Recruiting | Beijing Tide Pharmaceutical Co., Ltd | 508 | 2025-12-24 | 2026-03-11 |
| Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF HEC585, Placebo, Pirfenidone - Idiopathic Pulmonary Fibrosis (IPF) | Phase 3 | Recruiting | Sunshine Lake Pharma Co., Ltd. | 472 | 2025-10-27 | 2026-04-21 |
| A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast Nerandomilast - Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | Phase 3 | Active not recruiting | Boehringer Ingelheim | 1666 | 2024-09-26 | 2026-11-12 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis BMS-986278, BMS-986278 Placebo - Progressive Pulmonary Fibrosis | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 1057 | 2023-10-25 | 2026-04-23 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis BMS-986278, BMS-986278 Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 1255 | 2023-09-14 | 2026-03-24 |
| The Effect of N115 on Coughing in IPF Patients 20mM sodium pyruvate nasal spray, Saline Placebo control nasal spray - Idiopathic Pulmonary Fibrosis | Phase 3 | Completed | Cellular Sciences, inc. | 50 | 2023-08-15 | 2024-08-07 |
| SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) SC1011, Placebo comparator - Idiopathic Pulmonary Fibrosis | Phase 2 / Phase 3 | Recruiting | Guangzhou JOYO Pharma Co., Ltd | 210 | 2023-06-06 | 2024-11-19 |
| A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) BI 1015550, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Completed | Boehringer Ingelheim | 1177 | 2022-10-06 | 2025-10-20 |
| Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer - Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | Completed | United Therapeutics | 597 | 2022-09-12 | 2026-10-15 |
| Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer - Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | Enrolling by invitation | United Therapeutics | 1850 | 2022-09-06 | 2026-10-19 |
| Study to Assess Efficacy and Safety of Treamid for Patients With Reduced Exercise Tolerance After COVID-19 Treamid, Treamid twice a day, Treamid once a day - SARS-CoV-2 Infection, Lung Fibrosis | Phase 2 / Phase 3 | Unknown | PHARMENTERPRISES LLC | 412 | 2022-08-01 | 2022-08-25 |
| Pirfenidone to Prevent Fibrosis in Ards. Pirfenidone, Placebo - Acute Respiratory Distress Syndrome (ARDS) | Phase 3 | Recruiting | Università Vita-Salute San Raffaele | 130 | 2022-06-01 | 2026-05-08 |
Showing 20 of 78. Sign in to see all of them.
Idiopathic Pulmonary Fibrosis (58) · Lung Diseases, Interstitial (14) · Lung Diseases (7) · Fibrosis (6) · Scleroderma, Diffuse (5) · Scleroderma, Systemic (5) · Hypertension, Pulmonary (4) · Connective Tissue Diseases (3) · COVID-19 (2) · Cough (2) · Idiopathic Interstitial Pneumonias (2) · Respiratory Distress Syndrome (2) · Respiratory Tract Diseases (2) · Alveolitis, Extrinsic Allergic (1)
Respiratory Tract Diseases (76) · Lung Diseases (71) · Lung Diseases, Interstitial (64) · Pathological Conditions, Signs and Symptoms (41) · Pathologic Processes (39) · Fibrosis (33) · Skin and Connective Tissue Diseases (9) · Skin Diseases (8) · Connective Tissue Diseases (5) · Cardiovascular Diseases (4) · Hypertension (4) · Respiration Disorders (4) · Vascular Diseases (4) · Coronaviridae Infections (3)
pirfenidone (10) · nintedanib (5) · Bosentan (4) · Cyclophosphamide (4) · Acetylcysteine (3) · Rituximab (3) · Sildenafil Citrate (3) · treprostinil (3) · BI 1015550 (2) · GLPG1690 (2) · Interferon-gamma (2) · Nalbuphine (2) · PRM-151 (2) · ambrisentan (2) · interferon gamma-1b (2)
Boehringer Ingelheim (7) · Actelion (4) · Genentech, Inc. (4) · InterMune (4) · Assistance Publique - Hôpitaux de Paris (3) · Bristol-Myers Squibb (3) · Duke University (3) · Hoffmann-La Roche (3) · United Therapeutics (3) · Gilead Sciences (2) · Kyntra Bio (2) · Lakefront Biotherapeutics NV (2) · Royal Brompton & Harefield NHS Foundation Trust (2) · Trevi Therapeutics (2) · Alexandria University (1)
United States (44) · France (22) · Canada (20) · Germany (20) · Italy (20) · United Kingdom (18) · Australia (17) · China (17) · Mexico (17) · Spain (17) · South Korea (16) · Belgium (15) · Japan (15) · Netherlands (15) · Argentina (13)
Ganesh Raghu, MD (4) · Imre Noth, MD (4) · Fernando Martinez, MD (3) · James Loyd, MD (3) · Jay Ryu, MD (3) · Jesse Roman, MD (3) · Joe Lasky, MD (3) · Kevin Anstrom, PhD (3) · Kevin Brown, MD (3) · Rob Kaner, MD (3) · Talmadge King, MD (3)
PMID 35688625, PMID 28388260, PMID 26835133, PMID 31047956, PMID 33434107, PMID 37391667, PMID 25890798, PMID 26111071, PMID 26968970, PMID 27708114, PMID 30072107, PMID 30116539, PMID 30472023, PMID 31153107, PMID 31401786, PMID 31914963, PMID 33902584, PMID 21571362, PMID 24834811, PMID 24836310, PMID 26400368, PMID 27672117, PMID 28039616, PMID 28526798, PMID 28657784, PMID 30176872, PMID 30729456, PMID 30971229, PMID 31179008, PMID 32217654, PMID 33239000, PMID 36724330, PMID 37159034, PMID 38238788, PMID 38288082, PMID 41345848, PMID 42548365, PMID 42776606, PMID 16306520, PMID 16790698, PMID 17717203, PMID 17901413, PMID 17901414, PMID 18641099, PMID 19570573, PMID 19679600, PMID 19860915, PMID 19892673, PMID 20007927, PMID 20484178
2023 (3), U10HL080413 (3), 2015 (2), 2018 (2), 2019 (2), 2025 (2), 2016 (1), U01HL060839 (1), U01HL128954 (1), U24HL145265 (1)